
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has created AdvanceGxP to help companies consider good practice requirements earlier.
MHRA has designed the service to help companies developing emerging technologies. With innovation in medicines and advanced manufacturing moving quickly, MHRA observed that there may be limited precedent, guidance, or case studies showing how good practice principles apply. Such issues can cause uncertainty when companies are making decisions about facilities, processes, validation, and investment.
Seeking to prevent uncertainty, MHRA has secured funding from the Office for Life Sciences to develop and test AdvanceGxP. MHRA envisions the service, which will initially focus on advanced manufacturing technologies, helping innovators address regulatory and quality questions earlier. Through the service, MHRA aims to reduce the risk of redesign and delays and support more sustainable approaches.
MHRA will use the funding to recruit a specialist team and develop the service. The agency’s roadmap includes determining how organizations will access the service, which technologies and projects it will prioritize, and how it will connect with existing MHRA support. MHRA wants the service to connect seamlessly with its other offerings and regulatory pathways.
“AdvanceGxP will complement existing MHRA services and formal inspection,” the agency said. “It will not be an inspection or pre-inspection clearance, prescribe a particular technical solution, or guarantee a future regulatory or inspection outcome.”
When fully operational, the service will give organizations developing novel and potentially disruptive medicines technologies earlier access to practical, regulator-led good practice expertise. MHRA wants to help organizations explore how good practice principles may apply to their technologies and enable them to consider compliance before key development decisions are fixed.
MHRA has yet to start accepting AdvanceGxP applications and will limit capacity while it develops and tests the service. The agency will not charge companies to access the service as it progresses through the testing and pilot phases. Early AdvanceGxP projects will inform future charging arrangements and show how MHRA can run the service sustainably and potentially broaden access in the future.
Companies interested in accessing the service once it goes live can register with MHRA. The agency wants organizations developing novel or potentially disruptive medicines technologies, applications for AI, or sustainability elements to chemistry, manufacture, and controls to share details of their operations and innovations.
EMA posts Q&A on comparing quality attributes to show therapeutic equivalence
The European Medicines Agency (EMA) has answered 13 questions about comparing quality attributes to demonstrate therapeutic equivalence.
EMA addressed the queries in an update to Part 2 of its question-and-answer document on the quality of medicines. The new section of the Q&A builds on a July 2021 reflection paper that provided a statistical methodology for the comparative assessment of quality attributes in drug development.
Noting that the reflection paper lacked guidance on conducting and describing in vitro comparisons, EMA updated its Q&A to address the topics. The Q&A now provides a 10-part framework for comparing quality attributes in support of therapeutic equivalence. The framework covers each step from defining critical quality attributes that may affect safety and efficacy to producing a report detailing the findings.
Many of the other questions relate to individual parts of the framework. EMA is encouraging companies to choose similarity conditions based on the potential relationship between quality attributes and a product’s safety and efficacy. The guidance features two examples of approaches to similarity.
EMA explained that variability between batches within the test or reference population should be thoroughly investigated. When companies find no statistical between-batch variability, EMA supports the pooling of the results of batches of the same population. However, the agency cautioned that it may be difficult to rule out between-batch variability, especially in small datasets.
MHRA creates program to improve health outcomes for women
MHRA has launched a program to improve the safety and effectiveness of medicines and medical devices used by women.
Weeks after EMA identified priorities for ensuring women are better represented in drug development, MHRA has unveiled its own strategy for tackling evidence gaps related to women’s health. MHRA’s analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023 found pregnant and breastfeeding women were represented in 1.1% and 0.6% of studies, respectively.
With women of childbearing potential included in 33% of trials, MHRA has identified a need for policies that strengthen the evidence for healthcare technologies in women. The agency aims to ensure that differences in safety and effectiveness between men and women are identified and addressed.
MHRA’s program includes four strategic themes, including using data to improve health outcomes for women. The agency outlined an approach to real-world data and adopting advanced analytical methods to identify sex-based differences in outcomes. MHRA sees emerging modeling techniques and synthetic data as resources that can identify differences in outcomes, particularly in data-poor contexts.
Another theme covers encouraging innovation and quality for healthcare products for women. MHRA wants to use existing regulatory pathways to close gaps in women’s health, including by defining how its frameworks can stimulate product development and evidence generation.
EMA publishes principles and rules on its use of artificial intelligence
EMA has released principles and rules covering the use of artificial intelligence by its staff.
The agency launched its AI-enabled knowledge mining tool, Scientific Explorer, in March 2024 and rolled out Microsoft Copilot 365 in June 2026. EMA uses two versions of Microsoft’s AI tool — Copilot chat and Copilot 365 — to boost productivity. The agency has established three principles and a series of rules for staff using the technology.
EMA’s principles are human oversight, human-led decision-making, and ethical use. The agency created its rules to help staff uphold those principles. EMA’s rules include knowing when, and when not, to use AI tools. For example, staff can use AI to summarize and analyze information, provided it is not restricted, private, or confidential.
The agency is preparing guidance on using AI to generate and modify content. In line with the AI Act, EMA plans to set out requirements and good practices for using AI to produce written content, speeches, presentations, images, audio, and video. The guidance will cover both external and internal content.
MHRA unveils AI-powered tool for checking draft clinical trial protocols
MHRA has created an AI-powered tool for identifying potential issues in draft clinical trial protocols.
The agency plans to make the tool available to clinical trial sponsors and their representatives, who will use the technology before submitting protocols to identify issues that could lead MHRA to request more information. MHRA predicts that checking draft trial protocols before submission could save time during assessment.
The tool will assess whether MHRA is likely to require more information on unblinding in case of an emergency, clinical eligibility criteria, contraceptive requirements, and adverse event recording and reporting.
MHRA plans to open registration for access to the AI tool in late November. The agency will take a phased approach to onboarding sponsors.
Other News:
EFPIA has supported an IFPMA statement about implementing a global framework on chemicals. The European pharma trade group is calling for the science-based and risk-proportionate implementation of the framework, considering hazard, exposure, and conditions of use. EFPIA Statement

